Adcirca

pulmonary arterial hypertension PAH

Pharma

FDA approves Johnson & Johnson's combo pill Opsynvi for PAH

The FDA has signed off on Opsynvi, a tablet which combines J&J’s Opsumit and United's Adcirca, as a treatment for pulmonary arterial hypertension.

Kevin Dunleavy Mar 25, 2024 11:05am

In PAH patients, J&J's combo pill Opsynvi increases blood flow

Mar 6, 2023 9:37am

contract

Generics take aim at United's top-selling Remodulin

Mar 27, 2019 12:10pm